5 Minutes with Dr Louise Jackett
27 April 2016
To educate the next generation of melanoma researchers and doctors, MIA offers a number of unique clinical and research-based Fellowships each year. They are made possible thanks to the generosity of our donors.
Dr Louise Jackett is our 2016 Jani Haenke Melanoma Pathology Fellow.
Why did you apply for our Fellowship program?
I was drawn to the Melanoma Pathology Fellowship at MIA for the chance to work with a team at the forefront of melanoma research. Also, the diagnosis of melanoma and other melanocytic lesions under the microscope can be very difficult and this role allows me to learn from the best.
Tell us about your role with MIA?
I combine research activities and reporting of melanoma cases. Many of these cases are for patients treated at MIA but some are difficult cases that have come from pathologists nation-wide or internationally for expert opinion and I find these challenging and very interesting.
What drives you to come to work each day?
I find huge value in providing important information about patients’ health conditions. I also stay mindful of the generous donors who make my position possible.
Where did you work before coming to MIA?
I undertook my primary medical degree (MBBS, BMedSci) at the University of Tasmania and moved to Melbourne when I was a resident medical officer. There I pursued my anatomical pathology training over 5 years and recently gained fellowship with the Royal College of Pathologists of Australasia.
What are you hoping to achieve through your Fellowship at MIA?
I am hoping to increase my expertise in the tricky aspects of melanoma diagnosis, such as atypical melanocytic lesions and their distinction from melanoma. During the year I hope to publish on several projects that I am personally driving, as well as collaborating with many other MIA researchers by providing a pathological viewpoint and expertise.
What do you like to do in your spare time?
I like to counteract my sedentary microscope work by being very active! I love running, cycling and yoga.
Melanoma impacts more Australian teenagers and young adults than any other cancer. Dr James Wilmott, who has a young family of his own, has devoted his career to determining why these young Australians are susceptible to melanoma, and importantly, how to save them.
Melanoma Masterclass celebrates Australian luminaries who have transformed melanoma treatment worldwide
The extraordinary contribution of Australia’s most distinguished melanoma clinicians and researchers is being celebrated today.
Congratulations to Professor Richard Scolyer who was awarded the William O. Russell/Joanne Vandenberge Hill Award of Excellence in Pathology.
A Day in the Life Of... Serigne Lo, Research and BioStatistics Manager at Melanoma Institute Australia
Jay was your typical Aussie bloke – a truck driver, husband, dad and mate to many. Then he got melanoma. His cancer diagnosis turned his life upside down.
Clair faced an impossible choice – risk delivering her baby early, or delay potentially life-saving melanoma treatment
Little Madi misses her Dad. But she is determined to honour his memory and support life-saving melanoma research.
Toyota and country music fans invited to tip their hat to help tackle Australia's national cancer – melanoma
Melanoma Institute Australia has teamed up with the Toyota Country Music Festival 2018 in Tamworth!
MIA's dermatologist shares her knowledge with GPs on debunking myths and controversies on sunscreen.
Shannan Ponton thought he was invincible – he wasn’t. But his melanoma battle ended up saving more than his own life.
Researchers have demonstrated that immunotherapy is highly effective in treating a rare form of melanoma – a result that is surprising due to the nature of the tumour.
Innovation is helping to prevent melanoma developing in the first place.
Research from MIA is changing the way melanoma is managed worldwide and improving patient survival. Here are a few of our key highlights from this year.
A prestigious Fellowship has been awarded to fund research that will change the way melanoma treatment is assessed in the future.
New research from MIA has been published that forms the basis of the updated international guidelines for staging melanoma.
Professor William McCarthy AM has been awarded the Tom Reeve Award for Outstanding Contributions to Cancer Care.
Leading researchers from MIA have been acknowledged with three prestigious awards for excellence in melanoma research.
New research shows that patients who are more likely to respond to immunotherapy treatment have a greater diversity in their gut bacteria.
2018 will be bigger than ever, and a little bit different.
MIA's epidemiologist explains her new research on how country of residence should be considered when identifying melanoma risk.